Medical/Pharmaceuticals
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
2024 Interim Result Highlights (For the six months ended June 30, 2024) * Company published the efficacy and safety data of Cohort-G of TranStar102 study for osemitamab (TST001), plus checkpoint inhibitor and CAPOX as the first-line treatment of patients with locally advanced or metastatic G/GE...
2024-08-29 14:31
2480
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization
* Approval of ivonescimab for 2L+ EGFRm NSCL; HARMONi-A is the only phase III study that demonstrates significant benefit across all subgroups for PFS, and is also the only study to achieve the primary endpoint while showing a positive trend in OS benefit; HARMONi-A study presented in an oral p...
2024-08-29 04:20
2173
Asieris Pharmaceuticals Releases 2024 Semi-Annual Report, Highlighting Steady Progress in Launching Blockbuster Product for Precancerous Cervical Lesions and Continued Strengthening of Commercial Revenue Generation Capabilities
As of the date of this publication, APL-1702 has not been approved for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL); APL-1706 has not been approved for the diagnosis or surgical treatment of bladder cancer inChina. This article is intended to disclose the latest d...
2024-08-28 21:34
1941
Jenscare, with innovative TTVR, releases 2024H1 interim results
BEIJING, Aug. 28, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 endedJune 30, 2024...
2024-08-28 21:00
2066
Tigermed Reports 2024 Interim Results
HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...
2024-08-28 18:26
1662
Fosun Pharma Announces 2024 Interim Results
Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its o...
2024-08-28 18:10
1677
Harbour BioMed Announces 2024 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
2024-08-28 17:44
1655
Hyundai Bioscience to conduct phase 3 clinical trial for high-risk group of COVID-19 patients with the goal of emergency use authorization
* "Xafty® can be the only oral COVID-19 treatment that can be prescribed to high-risk group patients who cannot take Paxlovid®" * "While maintaining the current process for emergency use authorization for mild-to-moderate COVID-19 patients, Hyundai Bioscience will expedite Phase 3 clinical tr...
2024-08-28 17:29
1101
Achieva Medical Entered into an Exclusive Distribution Agreement with NowYon Medical
SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced that its wholly-owned subsidiary, Achieva Medical Limited ("Achieva Medical"), entered ...
2024-08-28 16:40
1055
Yunovia Announces IND Approval by the MFDS to Initiate Phase 1 MAD Study for the Small Molecule GLP-1 Agonist
SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has cleared the IND application of Phase 1 Multiple Ascending Dose (MAD) study for ID110521156, an oral...
2024-08-28 10:43
1375
GenScript Subsidiary Legend Biotech Achieves Breakthrough with Cilta-cel Approval in China, Offering New Hope for Multiple Myeloma Patients
PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (NASDAQ: LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research and manufacturing services, today announced that they have received approval from the Ch...
2024-08-27 22:28
1011
Keymed Biosciences Announces Interim Results for First Half of 2024
CHENGDU, China , Aug. 27, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced its interim results for the first half of 2024, along with a corporate update. Rapid development of our pipeline products Stapokibart (CM310) (IL-4Rα antibody) * In June 2024, the long-term e...
2024-08-27 21:10
1906
Sleep Specialists and Industry Leaders Converge at HoneyNaps Symposium
* The 1st HoneyNaps Sleep & Tech Symposium * Presentation of the 'SLEEP 2024 White Paper' and the Latest Advances in Sleep Research & Technology * Unveiling of HoneyNaps' New Brand Identity BOSTON, Aug. 27, 2024 /PRNewswire/ -- HoneyNapsUSA, Inc., an AI-driven sleep data analysis company, p...
2024-08-27 21:00
1577
111, Inc. to Participate in Fireside Chat with Water Tower Research on September 5, 2024
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today announced that it will parti...
2024-08-27 20:00
1325
HKBU research identifies potential of phosphocholine in counteracting PM2.5 toxicity in lung diseases
HONG KONG, Aug. 27, 2024 /PRNewswire/ -- A research team led by Hong Kong Baptist University (HKBU) has discovered that phosphocholine, an important component in the body's metabolism, could counteract the adverse effects of PM2.5 toxicity on lung cells. This discovery highlights the therapeutic ...
2024-08-27 13:28
1644
Mabwell Announces CDE Approval to Initiate Phase III Clinical Trial of 9MW2821 for Urothelial Carcinoma in Combination with PD-1 Inhibitor
SHANGHAI, Aug. 26, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for "a randomized, controlled, open-label, ...
2024-08-26 22:00
1767
Peijia Medical Announces 2024 Interim Results
HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months endedJune 30, 2024 ("the period") on August 23, 2024. ...
2024-08-26 20:30
2038
Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression SYDNEY, Aug. 26, 2024 /PRNewswire/ -- Actinogen Medic...
2024-08-26 20:30
1426
I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright ...
2024-08-26 19:00
900
Meihua International Medical Technologies Co., Ltd. to Present at LIVE! with Webull Corporate Connect: Virtual Healthcare Investment Webinar on August 28, 2024
YANGZHOU, China, Aug. 26, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that Xin "Stev...
2024-08-26 18:00
1477
Week's Top Stories
Most Reposted
Agoda Partners with Sands China to Boost Tourism
[Picked up by 318 media titles]
2024-09-05 11:00povo2.0, Japan's favourite digital telco, achieves highest user engagement and customer satisfaction rates with Circles' SaaS technology
[Picked up by 301 media titles]
2024-09-06 10:00The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
[Picked up by 299 media titles]
2024-09-05 11:21
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
[Picked up by 298 media titles]
2024-09-11 20:27VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
[Picked up by 292 media titles]
2024-09-11 15:20
Most Read
Agoda Partners with Sands China to Boost Tourism
2024-09-05 11:00
15471
The Beach Grill Unveils Exciting New Dishes: Elevating The Beachfront Dining Experience
2024-09-05 11:21
12890
UOB makes strong return to GBP covered bond market with GBP750m 3-year issuance
2024-09-06 12:02
10054
